Amiodarone-induced pulmonary toxicity


Submitted: 2 March 2011
Accepted: 24 May 2011
Published: 22 June 2011
Abstract Views: 1127
PDF: 1088
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Junichi Ochi Department of Pulmonary Medicine, Yokosuka Kyosai Hospital, Kanagawa, Japan, Japan.
  • Minoru Ohkouchi Department of Pulmonary Medicine, Yokosuka Kyosai Hospital, Kanagawa, Japan, Japan.
  • Yoshikazu Tsukada Department of Pulmonary Medicine, Yokosuka Kyosai Hospital, Kanagawa, Japan, Japan.
  • Shinichiro Tominaga Department of Pulmonary Medicine, Yokosuka Kyosai Hospital, Kanagawa, Japan, Japan.
  • Satoshi Takayama Department of Pulmonary Medicine, Yokosuka Kyosai Hospital, Kanagawa, Japan, Japan.
  • Yuko Taniguchi Department of Pulmonary Medicine, Yokosuka Kyosai Hospital, Kanagawa, Japan, Japan.
  • Yumi Miyamoto Department of Pulmonary Medicine, Yokosuka Kyosai Hospital, Kanagawa, Japan, Japan.
  • Naohiko Inase Department of Pulmonary Medicine, Yokosuka Kyosai Hospital, Kanagawa and Integrated Pulmonology, Tokyo Medical and Dental University, Japan, Japan.
Amiodarone-induced pulmonary toxicity is a critical and potentially fatal side effect of amiodarone. Our study was designed to reveal its clinical features, including KL-6, as an interstitial marker. The medical records of eight patients (five men and three women) with amiodarone-induced pulmonary toxicity, who had been referred to our hospital, were examined. The mean age at the initiation of amiodarone was 48 years (range, 54-87 years) and mean duration of medication prior to the development of pulmonary toxicity was 18 months (range, 7-33 months). Serum KL-6 was elevated in six of the eight patients with a range of 525-2915 U/mL. Chest computed tomography (CT) findings showed non-segmental consolidation and/or ground glass opacity. Foamy macrophages were found in bronchoalveolar lavage (BAL) fluids of all examined patients and in transbronchial lung biopsy (TBLB) specimens in half of the examined patients. We concluded that serum KL-6, chest CT findings, and foamy macrophages in BAL fluids and TBLB specimens will be helpful for the diagnosis of amiodarone-induced pulmonary toxicity.

Ochi, J., Ohkouchi, M., Tsukada, Y., Tominaga, S., Takayama, S., Taniguchi, Y., Miyamoto, Y., & Inase, N. (2011). Amiodarone-induced pulmonary toxicity. Chest Disease Reports, 4(1), e6. https://doi.org/10.4081/cdr.4.26

Downloads

Download data is not yet available.

Citations